Burkitt's lymphoma: The prevalence of HIV/AIDS and the outcome of treatment

Hesseling, Peter; Kouya, Francine; Katayi, E; Mbah, G; Wharin, Paul

doi:10.7196/samj.2017.v108i2.12441

Cited by 4 publications

(8 citation statements)

References 4 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, there is also an increased risk for Burkitt lymphoma in children living in areas where human immunodeficiency virus (HIV) infection is highly prevalent (Mutalima et al , ), adding additional co‐morbidity that could affect outcome. However in a study from Cameroon, the overall prevalence of HIV in children with Burkitt lymphoma was comparable to the general population (Hesseling et al , ). In middle‐income countries (MIC), there is no evidence of increased incidence in Burkitt lymphoma compared to the Western world, and there are no striking differences in clinical presentation compared to higher‐income countries, where the most common site of involvement is the abdomen (Ferreira et al , ; Steliarova‐Foucher et al , ).…”

Section: Epidemiologymentioning

confidence: 89%

Optimizing outcomes for children with non‐Hodgkin lymphoma in low‐ and middle‐income countries by early correct diagnosis, reducing toxic death and preventing abandonment

2019

View full text Add to dashboard Cite

In high-income countries, more than 90% of children with mature B-cell lymphomas are cured with frontline therapy. However, cure requires prompt and correct diagnosis, careful risk stratification, very intense chemotherapy and meticulous supportive care, together with logistical support for patients who live far from the cancer centre or face financial barriers to receiving care. In low-and middle-income countries (LMIC), cure rates range from 20% to 70% because of lack of diagnosis, misdiagnosis, abandonment of treatment, toxic death and excess relapse with reduced-intensity regimens. Fortunately, a wide range of successful interventions in LMIC have reduced these causes of avoidable treatment failure. Public awareness campaigns have led to societal awareness of childhood cancer; telepathology has improved diagnosis, even in remote areas; subsidized chemotherapy, transportation, housing and food have reduced abandonment; and hand hygiene, nurse training programmes and health system improvements have reduced toxic death. These interventions can be deployed everywhere and at low cost, so are highly scalable. Children and adolescents with Burkitt lymphoma can be cured in all countries by making a timely correct diagnosis, applying protocols adapted to the local context, preventing abandonment of therapy and avoiding toxic death. Reducing these causes of treatment failure is feasible and highly cost-effective everywhere.

show abstract

Section: Epidemiologymentioning

confidence: 89%

Optimizing outcomes for children with non‐Hodgkin lymphoma in low‐ and middle‐income countries by early correct diagnosis, reducing toxic death and preventing abandonment

2019

View full text Add to dashboard Cite

show abstract

“…Two of the reports addressed awareness, 7,11 10 addressed diagnosis, registration, and epidemiology, 5,[12][13][14][15][16][17][18][19][20] 18 addressed management and outcomes, 7,14,16,[21][22][23][24][25][26][27][28][29][30][31][32][33][34][35] four addressed supportive care, [36][37][38][39] five addressed palliative care, [40][41][42][43][44] four addressed advocacy and F I G U R E 1 Map of Cameroon showing location of dedicated pediatric oncology units partnerships, 35,37,45,46 and one addressed T&CM 39 (Supporting Information File S1).…”

Section: Resultsmentioning

confidence: 99%

“…Two of the reports addressed awareness, 7,11 10 addressed diagnosis, registration, and epidemiology, 5,12–20 18 addressed management and outcomes, 7,14,16,21–35 four addressed supportive care, 36–39 five addressed palliative care, 40–44 four addressed advocacy and partnerships, 35,37,45,46 and one addressed T&CM 39 (Supporting Information File S1).…”

Section: Resultsmentioning

confidence: 99%

“…7,21 Results regarding survival are fragmentary, but do indicate improved survival, especially for BL and nephroblastoma. 14,16,23,26,28,52 Proper follow-up is essential for measuring outcomes, and the CBCHS centers keep both paper-based and electronic records at dedicated childhood cancer registry offices at MBH, BBH, and BHM. Additional follow-up has been done by means of outreaches and by using mobile phones to establish specific outcomes.…”

Section: Management and Outcomes Of Common Childhood Cancersmentioning

confidence: 99%

“…ART and therapy based on cyclophosphamide have produced a long-term survival rate of 37.5%, with 91% of the patients being in the advanced stage of the disease. 23…”

Section: Management and Outcomes Of Common Childhood Cancersmentioning

confidence: 99%

See 2 more Smart Citations

Two decades of childhood cancer care in Cameroon: 2000–2020

Afungchwi

Kruger

Kouya

et al. 2021

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Background: Before the year 2000, there was no dedicated childhood cancer service in Cameroon. The aim of this study was to investigate the progress made with pediatric oncology care in Cameroon from 2000 to 2020.Method: A literature search was conducted for published articles on childhood cancer in Cameroon and relevant documents, and conference abstracts were reviewed. The articles were analyzed under the themes: awareness, diagnosis, epidemiology, treatment, outcome, advocacy, partnerships, traditional and complementary medicine, palliative care, and capacity building.Results: Low awareness on childhood cancer was addressed with education activities targeting the general population and health care professionals. Cancer diagnosis was achieved with cytology, histology, and simple imaging. Management for common and curable cancers was implemented with use of modified treatment regimens for lowand middle-income settings. Nutritional support was shown to mitigate the effects of malnutrition on treatment toxicity, and support was provided for transportation and accommodation. There was good collaboration between the pediatric oncology professionals nationally and twinning with international partners. Capacity building activities led to the availability of three pediatric oncologists and pediatric oncology-trained nurses. Advocacy nationally led to the support of the Ministry of Health with pediatric oncology-specific priority actions in the latest national cancer control plan. Conclusion:Childhood cancer should receive the necessary attention of health care policymakers in Cameroon. With continued commitment of government, nongovernmental organizations, charities, childhood cancer specialists, patient and parent groups, there should be an improved future for children with cancer in Cameroon.

show abstract

Progress in the Treatment of HIV-Associated Lymphoma When Combined With the Antiretroviral Therapies

Wang

Liu

2022

Front. Oncol.

View full text Add to dashboard Cite

With the wide use of combination antiretroviral therapy (cART), the life expectancy of HIV-infected individuals drastically improved. However, HIV infection and HIV-associated cancers were the most common causes of death in the HIV-infected populations. The HIV-associated cancers are divided into acquired immune deficiency syndrome (AIDS)-defining and non-AIDS-defining cancers based on the incidence among the HIV-infected patients. Among HIV-associated cancers, acquired immune deficiency syndrome-related lymphoma (ARL) is still the most common condition and the leading cause of HIV/AIDS-related deaths. Diffuse large B-cell lymphoma (DLBCL) and Burkitt’s lymphoma (BL) are the most common subtypes of the ARL. Although Hodgkin’s lymphoma (HL) is not considered as an AIDS-defining cancer, incidence of HL in HIV-infected individuals is higher than the general population. The review summarizes the new progress in the treatment of HIV-associated lymphoma.

show abstract

Burkitt's lymphoma: The prevalence of HIV/AIDS and the outcome of treatment

Cited by 4 publications

References 4 publications

Optimizing outcomes for children with non‐Hodgkin lymphoma in low‐ and middle‐income countries by early correct diagnosis, reducing toxic death and preventing abandonment

Optimizing outcomes for children with non‐Hodgkin lymphoma in low‐ and middle‐income countries by early correct diagnosis, reducing toxic death and preventing abandonment

Two decades of childhood cancer care in Cameroon: 2000–2020

Progress in the Treatment of HIV-Associated Lymphoma When Combined With the Antiretroviral Therapies

Contact Info

Product

Resources

About